PAION is a specialty pharmaceutical company that develops innovative products for sedation and anesthesia including commercialization.  

 

Learn more About PAION

Remimazolam

PAION's lead compound, Remimazolam, is an ultra-short-acting intravenous sedative and anesthetic that is currently in Phase III clinical development for procedural sedation and general anesthesia. Remimazolam has been investigated in more than 1,000 patients worldwide. 

PAION's Remimazolam

news

04/13/2016

Invitation including Agenda & Attendance

Invitation including Agenda & Attendance

Read more
04/13/2016

Explanatory report pursuant to Sections 289 (4) and Section 315 (4) of the...

Explanatory report pursuant to Sections 289 (4) and Section 315...

Read more
04/13/2016

Information on shareholders’ rights pursuant to Section 124a sentence 1 No. 2...

Information on shareholders’ rights pursuant to Section 124a...

Read more
04/11/2016

Press Release: PAION successfully completes patient recruitment in Phase III...

PAION successfully completes patient recruitment in Phase III...

Read more

PAION Chart